Considerations for pharmacoepidemiological analyses in the SARS‐CoV ‐2 pandemic-Reference-Cited by-同舟云学术

Considerations for pharmacoepidemiological analyses in the SARS‐CoV ‐2 pandemic

Published:2020-05-21 Issue:8 Volume:29 Page:825-831
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Pottegård Anton¹^ORCID,Kurz Xavier²^ORCID,Moore Nicholas³^ORCID,Christiansen Christian F.⁴^ORCID,Klungel Olaf¹⁵

Affiliation:

1. Clinical Pharmacology and Pharmacy, Department of Public HealthUniversity of Southern Denmark Odense Denmark

2. Data Analytics and Methods Task ForceEuropean Medicines Agency Amsterdam The Netherlands

3. Bordeaux PharmacoEpiUniversity of Bordeaux Bordeaux France

4. Department of Clinical EpidemiologyAarhus University Hospital Aarhus Denmark

5. Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS)Utrecht University Utrecht The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5029

Reference42 articles.

1. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists

2. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

3. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19

4. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

5. Chloroquine for COVID-19 Infection

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States;Clinical Epidemiology;2024-02

2. Treatment and care received by children hospitalized with COVID-19 in a large hospital network in the United States, February 2020 to September 2021;PLOS ONE;2023-07-11

3. Assessing heterogeneity of electronic health‐care databases: A case study of background incidence rates of venous thromboembolism;Pharmacoepidemiology and Drug Safety;2023-05-08

4. Bias in observational studies on the effectiveness of in hospital use of hydroxychloroquine in COVID‐19;Pharmacoepidemiology and Drug Safety;2023-04-24

5. Noninterventional studies in the COVID-19 era: methodological considerations for study design and analysis;Journal of Clinical Epidemiology;2023-01